Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi — Susan J. Robertson (2021) | RDL Network
Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi
Article 2021 en
Authors
SR
Susan J. Robertson
LO
Lisa Orme
RT
Rodrigo Teixeira
Abstract
1 min read
Given the response following crizotinib treatment observed in this case, the kinase fusion was believed to be functionally consequential in the patient's agminated Spitz nevi and likely the driver mutational event for growth of her nevi. The repurposing of crizotinib for GOPC-ROS1 Spitz nevi defines a new treatment option for these lesions, particularly in cases for which surgery is relatively contraindicated.
Féline P B Kroon, Marion C Kortekaas, Annelies Boonen, Stefan Böhringer, M. Reijnierse, Frits R. Rosendaal, N. Riyazi, M. Starmans, Franktien Turkstra, J. van Zeben, Cornelia F Allaart, M. Kloppenburg
Discussion(0)
No comments yet. Be the first to comment.